Literature DB >> 22710155

The bromodomain interaction module.

Panagis Filippakopoulos1, Stefan Knapp.   

Abstract

ε-N-acetylation of lysine residues (K(ac)) is one of the most abundant post-translation modifications (PTMs) in the human proteome. In the nucleus, acetylation of histones has been linked to transcriptional activation of genes but the functional consequences of most acetylation events and proteins recruited to these sites remains largely unknown. Bromodomains (BRDs) are small helical interaction modules that specifically recognize acetylation sites in proteins. BRDs have recently emerged as interesting targets for the development of specific protein interaction inhibitors, enabling a novel exiting strategy for the development of new therapies. This review provides an overview over sequence requirements of BRDs, known substrates and the structural mechanisms of specific K(ac) recognition.
Copyright © 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22710155     DOI: 10.1016/j.febslet.2012.04.045

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  132 in total

Review 1.  The bromodomain: from epigenome reader to druggable target.

Authors:  Roberto Sanchez; Jamel Meslamani; Ming-Ming Zhou
Journal:  Biochim Biophys Acta       Date:  2014-03-28

Review 2.  BET Epigenetic Reader Proteins in Cardiovascular Transcriptional Programs.

Authors:  Patricia Cristine Borck; Lian-Wang Guo; Jorge Plutzky
Journal:  Circ Res       Date:  2020-04-23       Impact factor: 17.367

3.  BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo.

Authors:  Mary A Morse; Karla K Balogh; Sarah A Brendle; Colin A Campbell; Mao X Chen; Rebecca C Furze; Isobel L Harada; Ian D Holyer; Umesh Kumar; Kevin Lee; Rab K Prinjha; Martin Rüdiger; Jonathan T Seal; Simon Taylor; Jason Witherington; Neil D Christensen
Journal:  Antiviral Res       Date:  2018-04-11       Impact factor: 5.970

4.  Selective Recognition of H3.1K36 Dimethylation/H4K16 Acetylation Facilitates the Regulation of All-trans-retinoic Acid (ATRA)-responsive Genes by Putative Chromatin Reader ZMYND8.

Authors:  Santanu Adhikary; Sulagna Sanyal; Moitri Basu; Isha Sengupta; Sabyasachi Sen; Dushyant Kumar Srivastava; Siddhartha Roy; Chandrima Das
Journal:  J Biol Chem       Date:  2015-12-11       Impact factor: 5.157

Review 5.  Mechanisms of action and regulation of ATP-dependent chromatin-remodelling complexes.

Authors:  Cedric R Clapier; Janet Iwasa; Bradley R Cairns; Craig L Peterson
Journal:  Nat Rev Mol Cell Biol       Date:  2017-05-17       Impact factor: 94.444

6.  Double duty: ZMYND8 in the DNA damage response and cancer.

Authors:  Fade Gong; Kyle M Miller
Journal:  Cell Cycle       Date:  2018-03-19       Impact factor: 4.534

7.  RNAs interact with BRD4 to promote enhanced chromatin engagement and transcription activation.

Authors:  Homa Rahnamoun; Jihoon Lee; Zhengxi Sun; Hanbin Lu; Kristen M Ramsey; Elizabeth A Komives; Shannon M Lauberth
Journal:  Nat Struct Mol Biol       Date:  2018-08-03       Impact factor: 15.369

Review 8.  The Bump-and-Hole Tactic: Expanding the Scope of Chemical Genetics.

Authors:  Kabirul Islam
Journal:  Cell Chem Biol       Date:  2018-08-02       Impact factor: 8.116

9.  Observed bromodomain flexibility reveals histone peptide- and small molecule ligand-compatible forms of ATAD2.

Authors:  Guillaume Poncet-Montange; Yanai Zhan; Jennifer P Bardenhagen; Alessia Petrocchi; Elisabetta Leo; Xi Shi; Gilbert R Lee; Paul G Leonard; Mary K Geck Do; Mario G Cardozo; Jannik N Andersen; Wylie S Palmer; Philip Jones; John E Ladbury
Journal:  Biochem J       Date:  2015-03-01       Impact factor: 3.857

10.  BRD7, a tumor suppressor, interacts with p85α and regulates PI3K activity.

Authors:  Yu-Hsin Chiu; Jennifer Y Lee; Lewis C Cantley
Journal:  Mol Cell       Date:  2014-03-20       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.